Pfizer Inc. said on April 7 the U.S. Food and Drug Administration extended the review of the company’s experimental atopic dermatitis drug by three months, the latest regulatory setback for a class of treatments known as JAK inhibitors.
Pfizer’s oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, continues to post strong clinical trial results as a treatment for atopic dermatitis.
Incyte presented the first Phase III data for ruxolitinib cream in atopic dermatitis. The research was presented at the Revolutionizing Atopic Dermatitis Virtual Symposium.
Pfizer’s oral Janus kinase 1 (JAK1) inhibitor abrocitinib hit the primary endpoint in a second Phase III study in patients 12 and older with moderate to severe atopic dermatitis.
